NCT01573910 arm group bdd661c031084442c69d71aafd9a5455 [clinicaltrials_resource:NCT01573910/arm-group/bdd661c031084442c69d71aafd9a5455]
arm group [clinicaltrials_vocabulary:arm-group]
NCT01573910 arm group bdd661c031084442c69d71aafd9a5455 [clinicaltrials_resource:NCT01573910/arm-group/bdd661c031084442c69d71aafd9a5455]
Bio2RDF identifier
NCT01573910/arm-group/bdd661c031084442c69d71aafd9a5455
Bio2RDF namespace
clinicaltrials_resource
Bio2RDF uri
http://bio2rdf.org/clinicaltri ...... d661c031084442c69d71aafd9a5455
description [clinicaltrials_vocabulary:description]
Ofloxacin ophthalmic solution, ...... a test-of-cure (TOC) at Day 9
identifier
clinicaltrials_resource:NCT01573910/arm-group/bdd661c031084442c69d71aafd9a5455
title
NCT01573910 arm group bdd661c031084442c69d71aafd9a5455
@en
type
label
NCT01573910 arm group bdd661c0 ...... 661c031084442c69d71aafd9a5455]
@en